These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 8099535)

  • 1. Haloperidol decanoate (Janssen) in the treatment of sexual deviations.
    Zbytovský J
    Cesk Psychiatr; 1993 Jan; 89(1):15-7. PubMed ID: 8099535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Haloperidol decanoate (Janssen) in the treatment of schizophrenia.
    Zbytovský J
    Cesk Psychiatr; 1993 Jan; 89(1):27-9. PubMed ID: 8099537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Haloperidol decanoate in the treatment of sexual deviations.
    Zbytovský J; Zapletálek M
    Act Nerv Super (Praha); 1989 Apr; 31(1):41-2. PubMed ID: 2571225
    [No Abstract]   [Full Text] [Related]  

  • 4. [Evaluation of the efficacy of haloperidol decanoate].
    Alvarez JV; Li Gambi M
    Acta Psiquiatr Psicol Am Lat; 1986 Sep; 32(3):233-6. PubMed ID: 2884807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Bromperidol decanoate in the residual phase of schizophrenia].
    Smeraldi E; Cocconcelli C; Canova L; Faravelli C; Marchetti FP; Mariani G; Rapisarda V
    Minerva Psichiatr; 1996 Mar; 37(1):39-44. PubMed ID: 8926856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Evaluation of the efficacy of haloperidol decanoate in the treatment of chronic psychotic hospital patients].
    Marchant N; Caruso S; Cuervo L; Brizuela A
    Acta Psiquiatr Psicol Am Lat; 1985 Mar; 31(1):37-41. PubMed ID: 2864788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A practical loading dose method for converting schizophrenic patients from oral to depot haloperidol therapy.
    Wei FC; Jann MW; Lin HN; Piao-Chien C; Chang WH
    J Clin Psychiatry; 1996 Jul; 57(7):298-302. PubMed ID: 8666571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Haloperidol decanoate in replacing combinations of antipsychotic agents in the treatment of chronic schizophrenics].
    Youssef HA
    Acta Psiquiatr Psicol Am Lat; 1984 Dec; 30(4):297-304. PubMed ID: 6152573
    [No Abstract]   [Full Text] [Related]  

  • 9. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmaco-clinical correlations during fluoxetine administration in patients with depressive schizophrenia treated with haloperidol decanoate].
    Viala A; Aymard N; Leyris A; Caroli F
    Therapie; 1996; 51(1):19-25. PubMed ID: 8762216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amoxapine as an antipsychotic: comparative study versus haloperidol.
    Chaudhry IB; Husain N; Khan S; Badshah S; Deakin B; Kapur S
    J Clin Psychopharmacol; 2007 Dec; 27(6):575-81. PubMed ID: 18004123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of chronic antipsychotic treatment on sexual behaviour, hormones and organ size in the male rat.
    Zhang X; Zhang Z; Cheng W; Mou X; Reynolds GP
    J Psychopharmacol; 2007 Jun; 21(4):428-34. PubMed ID: 17050660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia.
    Kane JM; Lauriello J; Laska E; Di Marino M; Wolfgang CD
    J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S29-35. PubMed ID: 18334910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parenteral haloperidol for rapid control of severe, disruptive symptoms of acute schizophrenia.
    Reschke RW
    Dis Nerv Syst; 1974 Mar; 35(3):112-5. PubMed ID: 17894080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].
    Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M
    Encephale; 1995; 21(6):417-24. PubMed ID: 8674466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic properties of haloperidol decanoate.
    Alda M; Pavlovsky P; Kristofikova Z; Dufkova D
    Act Nerv Super (Praha); 1989 Apr; 31(1):38-9. PubMed ID: 2571223
    [No Abstract]   [Full Text] [Related]  

  • 17. [Risperidone in the treatment of chronic schizophrenia: multicenter study comparative to haloperidol].
    López Ibor JJ; Ayuso JL; Gutiérrez M; Guimon J; Herraiz ML; Chinchilla A; Ayuso JL; González Pinto A; Eguiluz I; Fernández A
    Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1996; 24(4):165-72. PubMed ID: 8984849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Striatal dopaminergic D2 receptor occupancy and clinical efficacy in psychosis exacerbation: a 123I-IBZM study with ziprasidone and haloperidol.
    Corripio I; Catafau AM; Perez V; Puigdemont D; Mena E; Aguilar Y; Carrió I; Alvarez E
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Jan; 29(1):91-6. PubMed ID: 15610950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term efficacy and safety comparison of sertindole and haloperidol in the treatment of schizophrenia. The Sertindole Study Group.
    Daniel DG; Wozniak P; Mack RJ; McCarthy BG
    Psychopharmacol Bull; 1998; 34(1):61-9. PubMed ID: 9564200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of omega-3 fatty acids, vitamins E and C supplementation on treatment outcome and side effects in schizophrenia patients treated with haloperidol: an open-label pilot study.
    Sivrioglu EY; Kirli S; Sipahioglu D; Gursoy B; Sarandöl E
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1493-9. PubMed ID: 17688987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.